Xenon Pharmaceuticals (XENE) voluntarily halted enrollment in a handful of studies Friday due to several unexpected side effects. The biotech stock crashed to a six-month low. The drug at the center of the debacle is azetukalner, which Xenon is hoping will soon gain approval to treat epilepsy. Xenon stock shot 50% higher on March 9 following positive results for azetukalner…
Copyright ©2026 Investor's Business Daily, LLC. All rights reserved. 87990cbe856818d5eddac44c7b1cdeb8
